BIOVERATIV INC (BIVV) Now Covered by Analysts at Royal Bank Of Canada
Royal Bank Of Canada started coverage on shares of BIOVERATIV INC (NASDAQ:BIVV) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The firm issued a sector perform rating and a $59.00 price target on the biotechnology company’s stock.
Several other equities analysts have also commented on BIVV. William Blair began coverage on shares of BIOVERATIV INC in a research report on Wednesday, June 28th. They set a market perform rating for the company. Cowen and Company upgraded shares of BIOVERATIV INC from a market perform rating to an outperform rating in a research report on Monday, July 10th. Jefferies Group LLC reiterated a buy rating on shares of BIOVERATIV INC in a research report on Friday, June 30th. Zacks Investment Research upgraded shares of BIOVERATIV INC from a hold rating to a strong-buy rating and set a $73.00 price objective for the company in a research report on Tuesday, July 25th. Finally, Credit Suisse Group upgraded shares of BIOVERATIV INC from an underperform rating to a neutral rating and increased their price objective for the company from $47.00 to $52.00 in a research report on Wednesday, May 24th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Hold and an average price target of $60.33.
BIOVERATIV INC (BIVV) opened at 55.18 on Thursday. The stock has a market cap of $5.97 billion and a PE ratio of 13.12. BIOVERATIV INC has a 12 month low of $40.00 and a 12 month high of $64.41. The company has a 50-day moving average of $56.37 and a 200-day moving average of $54.74.
BIOVERATIV INC (NASDAQ:BIVV) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.17. The company had revenue of $289.10 million for the quarter, compared to the consensus estimate of $269.00 million. During the same quarter in the prior year, the company posted $0.59 EPS. BIOVERATIV INC’s revenue was up 37.5% compared to the same quarter last year. On average, equities analysts forecast that BIOVERATIV INC will post $2.89 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “BIOVERATIV INC (BIVV) Now Covered by Analysts at Royal Bank Of Canada” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/18/bioverativ-inc-bivv-now-covered-by-analysts-at-royal-bank-of-canada.html.
In other news, Director Brian S. Posner bought 1,000 shares of BIOVERATIV INC stock in a transaction dated Wednesday, August 9th. The shares were acquired at an average price of $59.19 per share, with a total value of $59,190.00. Following the completion of the purchase, the director now owns 6,693 shares in the company, valued at approximately $396,158.67. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Diantha Duvall sold 818 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total transaction of $49,464.46. Following the completion of the sale, the insider now directly owns 2,128 shares in the company, valued at approximately $128,680.16. The disclosure for this sale can be found here.
BIOVERATIV INC Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Stock Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related stocks with our FREE daily email newsletter.